Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc.DailyFinanceThe ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targeted bio…
Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc.The Herald | HeraldOnline.comThe ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect …
Lupus Nephritis Tamed Without SteroidsMedPage TodayA combination regimen of rituximab (Rituxan) and mycophenolate mofetil (CellCept) successfully controlled lupus nephritis in 90% of patients without the need for oral corticosteroids, a prospective obs…
23rd annual report: Top 100 medicine highlightsPharmaLive (press release) (subscription)Roche reported Rituxan/MabThera (rituximab) sales of SFr1.7 billion during first-quarter 2013, up 6 percent compared to 1Q 2012. Sales improved due to increased use…
Kidney Function Declines Faster in Black PatientsMedPage Today… from the Science, Health, and Environmental Reporting program at New York University. MOST READ IN Nephrology. 1. Elderly Decline Rapidly After Starting Dialysis. 10/14/2009. |. 0. 2. Ri…
|
Curis’ Differentiated Oncology Approach Is Worth More Than The Market Suggests
Seeking Alpha Idelalisib generated a complete response rate of 19% and an overall response rate of 97% when combined with rituximab in treatment-naive older patients with chronic lymphocytic leukemia. And Infinity, at the meeting of the American Society for Clinical … |
|
Stocks in Focus: Windstream Corporation, Yahoo! Inc.(NASDAQ:YHOO …
US Market Buzz … idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing … |
|
Otic lichen planus related to persistent hearing loss, otorrhea
Healio One patient with severe otic LP affecting the ear, oral cavity, esophagus and genital areas responded to rituximab. “Otic LP … should be considered in differential diagnosis of relentless otorrhea and external auditory canal stenosis,” the researchers … |
Progression-free Survival 96% in CLL With IbrutinibMedscapeJennifer Brown, MD, assistant professor in the Department of Medicine at Harvard Medical School in Cambridge, Massachusetts, presented interim data on ibrutinib in combination with bendamustine…
Universal HBV Screening Is Cost-Effective in LymphomaMedscapeIn patients who were going to receive rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, screening all patients for HBV decreased the rate of HBV reac…